Resource aims to boost essential medicine accessibilityMarch 17, 2020A new resource from the World Small Animal Veterinary Association (WSAVA) hopes to arm veterinary professionals with the medications they need to provide companion animals with the best care possible.
SPONSORED CONTENTImprove their microbiome, improve quality of lifeWith 70% of a dog’s immune system in the GI tract, you need confidence in their microbiome support — which is why Hill’s developed ActivBiome+. + Learn More
Canine atopic dermatitis meds revenue set to surpass $2.4B by 2029February 21, 2020Veterinary medicine will see staggering growth in the global market value of canine atopic dermatitis treatment in the coming decade.
Veterinary insight drives pet medication industryFebruary 19, 2020America’s veterinary market has a direct impact on the country’s $9.8 billion pet medications industry.
Elanco divests canine ear treatment in $135-million dealJanuary 6, 2020A major player in the animal health industry has just unloaded its proprietary treatment for canine otitis externa in an all-cash deal, totaling $135 million.
Antimicrobials see second-lowest year for salesDecember 11, 2019Antimicrobials for use in food-producing animals have maintained low volume of sales and distribution in recent years.
AAVMC, Merck division unite on AMR projectDecember 10, 2019The Association of American Veterinary Medical Colleges (AAVMC) has joined forces with MSD Animal Health, a division of Merck & Co., on an international grant program designed to mitigate global health concerns surrounding antimicrobial resistance (AMR).
Managing OA with anti-NGF therapyNovember 22, 2019It is clear to any practicing veterinarian there is a very limited toolbox when it comes to effective treatments for osteoarthritis (OA) pain in dogs and cats. The need, however, is quite apparent.
Bacterial infections: Resistance isn't futileOctober 17, 2019Primary health-care providers in veterinary and human medicine face the same problem when it comes to client expectations.
Walmart launches pet pharmacy, opening more in-store clinicsMay 7, 2019Walmart says it is launching its first pet pharmacy and opening more in-store veterinary clinics. "These clinics offer affordable, high quality, and convenient services to save customers as much as 40 to 60 percent on vaccines and minor illness packages and exams," the company wrote on its website. The news comes at a time when private practices are already competing with online pharmacy retailers that are digging into their revenue. According to Walmart, it will provide low-cost prescriptions for dogs, cats, horses, and livestock through WalmartPetRx.com. The website will offer more than 300 brands to treat conditions such as flea and tick, heartworm, allergy, and arthritis, which are main sources of income for veterinarians. Walmart will also offer home delivery. The option to pick up pet prescriptions in-store will be available later this month, as the retailer is stocking more than 4,500 of its pharmacies with the 30 most requested pet medications. Walmart says it will be opening nine new clinics in the Dallas-Fort Worth area, Tex., in late May and June. It has plans to expand to more than 100 locations over the next 12 months.
What does 503B compounding mean for the future of veterinary medicine?April 3, 2019Modern compounding—often referred to as 503A—is a niche business, providing patient-specific formulations to satisfy individual needs. Because commercially available drugs are marketed almost exclusively for humans, compounding has become an essential resource for veterinary medicine. Veterinarians often depend on 503A pharmacies to provide preparations at lower concentrations and in more palatable dosage forms to optimize treatment for their patients. However, without proper management and regulations, 503A compounding can potentially be detrimental. Presently, 503A pharmacies are not required to adhere to Current Good Manufacturing Practice (cGMP) objectives put forth by the U.S. Food and Drug Administration (FDA) to ensure pharmaceuticals achieve a specified standard of safety. The quality of products produced in a 503A facility depend on the pharmacy's voluntary conformance with cGMP, which can be substantially cost-prohibitive, requiring anywhere from $50,000 to $100,000-plus of investment for a single formulation. Testing on raw materials and finished products may be performed to an extent depending on the facility, but the data are often incomplete, testing only one or two factors while omitting others that would affect the product's overall quality. The variability of cGMP compliance from pharmacy to pharmacy paves the way for omissions in procedures that can lead to patient harm. …
